|
|
 |
|
Viewing report
|
|
|
|
The Asian Cancer Market Outlook to 2010
Business Insights, Dec 2005
The Asian Cancer Market Outlook to 2010 is a new management report which provides an in-depth analysis of growth brands, product sales forecasts, epidemiology and future market leaders over the period 2005-2010 in nine markets; China, Taiwan, South Korea, Singapore, the Philippines, Malaysia, Thailand, Indonesia and India.
The differences in economic development and market potential across the region have led to the creation of a dynamic market for branded products, both innovative and non-innovative, and locally imported generic products, both biologic and conventional. The increasing presence of local players in the Asian market highlights the generics threat to major oncology products which marketers need to overcome in order to ensure success.
Globally successful products are no longer guaranteed a competitive position in the Asian market; use this latest report to identify the cancer market trends in developed and emerging Asian countries, assess the dominant forces driving market growth and develop potential growth and diversification strategies in this region over the period 2005-2010.
Geographic coverage...
- China
- India
- Indonesia
- Malaysia
- Singapore
- South Korea
- Taiwan
- Thailand
- The Philippines
Nine major cancers...
- Prostate
- Lung
- Lymphoma
- Leukemia
- Colorectal
- Pancreatic
- Breast
- Ovarian
- Uterin
'Must have' statistics and analysis in this report
This report provides:
- Forecasts and analysis using gold standard IMS sales data of the major products in the Asian cancer market over the period 2005-2010 for the nine major cancers.
- Overview of healthcare programs and pharmaceutical spending across the nine Asian cancer markets, as well as an examination of trends and future prospects.
- Company analysis and market share of the top eight players in the Asian cancer market, including Roche, Novartis, Sanofi-Aventis and Pfizer.
- Epidemiological analysis and forecasts for the nine major cancers across the nine Asian markets, including China, South Korea, Singapore Taiwan, Indonesia and the Philippines.
- Detailed analysis across four classes of cancer products, and late-stage pipelines in these classes.
Your questions answered
- What will be the major growth indications in the Asian cancer market over the period 2005-2010?
- How have recent major launches from Roche, Novartis, and Sanofi-Aventis performed across Asia?
- Which companies will become the key players in the Asian cancer market over the period 2005-2010?
- Which products will be impacted by generic competitors over the period 2005-2010?
- Which markets in Asia are the major growth drivers for cancer sales over the period 2005-2010?
- Which of the major cancers are forecast to have the highest incidence levels across Asian markets over the period 2005-2010?
- What will the competitive landscape in the major cancers (prostate, breast, lung, colorectal, ovarian, leukemia, pancreatic, lymphoma, uterine) look like in the Asian region in 2010?
Actionable strategies to drive your profits forward
- Save valuable time and research budget with this report's epidemiological analysis and forecasts across the nine Asian cancer markets, examination of the four major classes of cancer products using IMS data, and breakdown of the eight largest cancer franchises active in the Asian region.
- Quickly understand how marketers are confronting competitive changes across Asian cancer markets and evaluate how recent events are affecting the performance of major products.
- Benchmark the successful oncology strategies of leading players including Novartis, Roche and Pfizer by analyzing up-to-date competitive intelligence across nine Asian cancer markets.
- Optimize your strategic positioning across Asian cancer markets forecast to have the greatest increase in incidence and develop strategies to meet the needs of these growing markets.
- Identify future market leaders by using head-to-head comparisons of newly launched cancer products across Asian markets to understand which companies will have a presence among key indications over the next six years.
Customers who bought this item also bought
The Cancer Market Outlook to 2012
The Cancer Market Outlook to 2010
The Cancer Market Outlook to 2011
The Eastern European Cancer Market Outlook to 2010
Drug Delivery in Cancer - Technologies, Markets and Companies
The Latin American Cancer Market Outlook to 2010
Commercial Insight: Antihormonal Cancer Therapies
Cancer Therapeutics Markets
The Cancer Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
The Cancer Market Outlook to 2009
The Cancer Market Outlook to 2008
|
|
|
|
